arrow
P

Paula R. Clemens

university of pittsburgh school of medicine
H指数:55
被引数:1.5万

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Muscle function, linear growth, and bone health during 30 months of vamorolone, prednisone, and deflazacort treatment for Duchenne muscular dystrophy: a comparative study

杜氏肌营养不良症治疗30个月期间vamorolone、泼尼松和去氟可的松治疗对肌肉功能、线性生长和骨骼健康的影响:一项比较研究

2026-10-290
OAAI
Adrenal insufficiency in individuals with Duchenne muscular dystrophy treated with glucocorticoids: Insights from the past, current challenges, and future directions

glucocorticoids治疗的患者中肾上腺功能不全:来自过去的见解、当前挑战和未来方向

2026-09-220
PRE
Prednisone, not vamorolone, suppresses novel serum bone and cartilage biomarkers associated with growth failure in children with Duchenne muscular dystrophy

泼尼松,而非vamorolone,抑制与杜氏肌营养不良儿童生长迟缓相关的血清骨骼和软骨新型生物标志物

2026-08-030
OA
Adrenal Suppression in Duchenne Muscular Dystrophy: Management Strategies Incorporating Novel Steroid Vamorolone

杜氏肌营养不良症中的肾上腺抑制:整合新型类固醇vamorolone的管理策略

2026-02-011
PRE
Mineralocorticoid receptor antagonism of vamorolone: Evidence from LIONHEART and VISION-DMD clinical trials

de Vera A, Clemens PR, Dang UJ, Dutreix C, Gresko E, Guglieri M, et al. 醛固酮受体拮抗作用:来自LIONHEART和VISION-DMD临床试验的证据。Steroids. (2025) 223:109689. doi: 10.1016/j.steroids.2025.109689。

2025-11-012
OAAI
Exposure-response of serum biomarkers to vamorolone, a dissociative corticosteroidal anti-inflammatory drug, in 4-to <7-year children

vamorolone(一种解离性皮质类固醇抗炎药)对4至<7岁儿童血清生物标志物的暴露-反应关系

2025-11-010
OAAI
Efficacy and safety of avalglucosidase alfa in patients with late-onset Pompe disease after 145 weeks of treatment during the COMET trial

avalglucosidase alfa在COMET试验中治疗晚期发作型庞贝病145周后的疗效与安全性

2025-08-160
OA
Switching Enzyme Replacement Therapy for Late-Onset Pompe Disease From Alglucosidase Alfa to Cipaglucosidase Alfa Plus Miglustat: Post Hoc Effect Size Analysis of PROPEL

将晚期庞贝病糖苷酶替代疗法从阿糖苷酶alfa切换为西帕糖苷酶alfa联合米格鲁斯坦:PROPEL研究的后效分析

2025-05-070
OA
Analysis of human urinary extracellular vesicles reveals disordered renal metabolism in myotonic dystrophy type 1

对人类尿液外泌体的分析揭示了强直性肌营养不良1型中的肾代谢紊乱

2025-03-050
OA
A Parent Project Muscular Dystrophy-sponsored International Workshop Report on Endocrine and Bone Issues in Patients with Duchenne Muscular Dystrophy: An Ever-changing Landscape

Parent Project Muscular Dystrophy资助的国际研讨会报告:杜氏肌营养不良症患者的内分泌和骨骼问题:一个不断变化的领域

2025-01-260
PRE
Efficacy and Safety of Vamorolone Over 48 Weeks in Boys With Duchenne Muscular Dystrophy

Vamorolone在Duchenne肌营养不良症男孩中48周的疗效和安全性

2024-03-1211
OAAI
Findings from the Longitudinal CINRG Becker Natural History Study
2023-11-175
OAAI